Pine nuts and goats milk should be on food allergy lists, researchers say
It comes as a study highlighted eight foods currently not included on the list for mandatory allergy labelling but which are regularly involved in cases of anaphylaxis, a life-threatening allergic reaction that can happen very quickly.
Experts in France analysed food-induced anaphylaxis cases reported to the Allergy Vigilance Network from 2002–2023.
In almost 3,000 cases, some 413 were caused by eight emerging allergens without mandatory labelling, including two deaths, according to study author Dominique Sabouraud-Leclerc.
'We therefore believe it is time to review the list of the 14 foods with mandatory labelling to include at least the most severe of these emerging food allergens,' she said.
Writing in the journal of Clinical and Experimental Allergy, researchers suggest four of these foods – goat and sheep milk, buckwheat, peas and lentils, and pine nuts – should be included on allergen listings.
This is due to their 'frequency, severity, recurrence, and potential for hidden exposure', they added.
The recurrence rate – which means the same allergen caused a number of reactions in the same patient – ranged from 7.3% for peas and lentils and 56% for goat and sheep milk.
Researchers also warned other ingredients to be wary of include kiwi, apple, beehive products like pollen, and alpha-gal, which can be found in red meat.
In the UK and EU, food businesses are required to highlight 14 major allergens on packaging. These are:
– Celery– Cereals containing gluten, such as wheat, rye, barley and oats– Crustaceans like prawns, crabs and lobsters– Eggs– Fish– Lupin, a legume related to peanuts– Milk– Molluscs like mussels and oysters– Mustard– Peanuts– Sesame– Soybeans– Sulphur dioxide and sulphites– Tree nuts like almonds, hazelnuts, walnuts, brazil nuts, cashews, pecans, pistachios and macademia nuts
Anaphylaxis symptoms usually start within minutes of coming into contact with an allergen and can include swelling of the throat and tongue, trouble breathing and fainting.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
ReAlta Life Sciences Secures European Orphan Drug Status for Graft-vs-Host Disease Treatment
By Karen Roman ReAlta Life Sciences, Inc. said it was granted Orphan Drug Designation by the European Medicines Agency (EMA) for RLS-0071 (pegtarazimod), to treat Graft-versus-Host Disease (GvHD). The designation was supported by preliminary data from the company's Phase 2 trial and follows FDA Orphan Drug and Fast Track designations received in 2024, it stated. 'Receiving EMA Orphan Drug Designation represents a significant new regulatory milestone in our efforts to address the urgent unmet need in aGvHD, and we are particularly encouraged by the EMA's positive feedback to our initial cohort of Phase 2 data,' said David Marek, ReAlta's CEO. READ MORE Final Agenda: LA CorpGov Forum Sept 4 Featuring Sports and Entertainment Never Miss our Weekly Highlights Contact: Exec Edge Editor@ Click to follow us on LinkedIn
Medscape
6 hours ago
- Medscape
Pricey Drugs Unlikely to Solve Dementia
This transcript has been edited for clarity. Dear colleagues, I'm Christoph Diener from the faculty of medicine at the University of Duisburg-Essen, in Germany. In this month's video, I would like to concentrate on the topic of dementia. We made tremendous progress in the diagnosis of Alzheimer's disease, not only at a time when patients show symptoms but also in the preclinical phase of the disease. Biomarkers and Lifestyle We have new biomarkers in cerebrospinal fluid with amyloid and tau PET, and more recently, we have now biomarkers in plasma. One is p-tau217, and this has shown a high sensitivity for the diagnosis of Alzheimer's disease and a good correlation with cerebrospinal fluid markers, as published recently in Neurology . A second aspect is we know that there are about 14 different lifestyle factors and comorbidities that increase the risk for mild cognitive impairment, dementia, and in particular, Alzheimer's disease. The most frequent ones — as you know — are vascular risk factors, hearing loss, smoking, high alcohol intake,obesity, and nutrition. Unfortunately, for most of these correlations, there have been no prospective randomized trials to show that management or treatment of these risk factors or comorbidities would really decrease the risk of Alzheimer's disease. Just to give you an example, there is one study from the US published in Neurology with more than 100,000 participants, and they showed that consumption of red meat significantly increases the risk of dementia. We have in the past not really considered lifestyle factors enough to prevent Alzheimer's disease. Herpes Zoster and Cognitive Impairment There are very interesting findings on the correlation between Herpes zoster and the increased risk of cognitive impairment and have now several studies with hundreds of thousands of patients in the US, in the UK and Australia, which showed that, if someone has Herpes zoster infection, over the next 13 years, the risk of dementia is increased between 15% and 30%. The more interesting feature is that obviously vaccination against Herpes zoster reduces the risk of have been several studies, including one in Wales with almost 300,000 participants. When the vaccination was introduced, participants born before 1933 were not vaccinated, while 50% of those born after 1933 were vaccinated. After 7 years, the diagnosis of dementia was reduced by 3.5% in vaccinated relative risk reduction for dementia was 20%. Another aspect is which vaccine. The study from the United States with more than 100,000 people observed over 6 years showed that recombinant vaccine is more effective in preventing cognitive impairment and dementia compared to the traditional live vaccine. The risk reduction was 17%. GLP-1 Drugs and Anti-Amyloids We have a totally new class of medicines to treat diabetes and obesity: the GLP-1 receptor agonists. There is indirect evidence that they might also be beneficial for the prevention of dementia. One publication in JAMA Neurology looked at a database of more than 33,000 patients treated with GLP-1 receptor agonistsand 34,000 treated with SGLT2 inhibitors compared with standard therapy. For both substances, there was a 35%-45% reduction in the risk of Alzheimer's dementia and other dementias compared to standard therapy. This has to be shown in one of the ongoing trials with GLP-1 receptor agonists. Let me mention the new beta-amyloid antibodies, lecanemab and donanemab. They have been approved both in the United States and in Europe for the treatment of early stages of Alzheimer's disease. This is a complicated business because you need biomarkers and amyloid PET for the diagnosis, you need regular intravenous administration, and you need MR controls to check for Amyloid-related imaging abnormalities. At the recent Alzheimer's Congress in Toronto, for both substances, long-term data were presented for a time period of three to 4 years. They showed that with increasing time of treatment, there is also an increase, obviously, in efficacy if the data are compared with a database, not within the randomized trials, because these were open-label, long-term studies. With donanemab, it was interesting that, in more than 75% of the patients, there was no longer amyloid detected on PET. The other important issue is that there is now a new application of donanemab that is subcutaneous. Spend Money on Lifestyle At the end of the day. I'm not really sure whether this is an effective treatment if we consider cost and risk, and I think a healthcare system would be better advised to invest all this money into teaching of at-risk persons, in particular, to have an impact on lifestyle. I'm aware that, in low-income people, this is extremely difficult, because they cannot afford healthy food and they cannot afford to pay for a gym for regular exercise. I think we can do much better, in particular, in treating comorbidities like obesity, diabetes, hypertension, high cholesterol, and so on. Dear colleagues, this is a short update on what has happened recently in the field of dementia. I'm Christoph Diener from the University of Duisburg-Essen Medical School. Thank you very much for listening and watching.
Associated Press
7 hours ago
- Associated Press
BioEcho Unveils EchoLUTION™ Cell Culture RNA Kit, Delivering Superior Quality and Speed for Research
BioEcho launches new EchoLUTION™ Cell Culture RNA kit, offering superior quality and speed for academic and biopharma research in under 10 minutes. COLOGNE, GERMANY, August 21, 2025 / / -- BioEcho Life Sciences GmbH, an Admera Health company, has launched its new EchoLUTION™ Cell Culture RNA purification kit. This kit utilizes the revolutionary one-step EchoLUTION™ technology to deliver superior RNA quality with high recovery rates and more usable reads in downstream applications. The purification method drastically reduces hands-on time and overall turnaround, with a workflow of under 10 minutes. The launch of the Cell Culture RNA kit follows the successful introduction of the EchoLUTION™ FFPE RNA kit in late 2023. Both kits are critical tools for academic and biopharma researchers, offering significant cost savings by eliminating multiple wash steps and reducing the use of consumables. The new kit is available in 96- and 384-well plate formats and can be used with a variety of sample types. This new approach inverts the logic of traditional purification, which has for decades relied on harsh, inefficient binding techniques. By retaining impurities and allowing the nucleic acids to pass through in a single step, the method eliminates multiple wash steps, which are a major source of sample loss and time consumption. 'We are proud to introduce a product that will significantly improve the efficiency and quality of nucleic acid purification workflows,' said Dr. Sarah Eckenrode, General Manager of BioEcho. 'The EchoLUTION™ Cell Culture RNA kit is a game-changer for academic and biopharma researchers who need fast, reliable, and cost-effective solutions. We developed this kit to address the common bottlenecks associated with traditional methods, providing a gentle yet powerful alternative that truly reveals the unseen.' The new EchoLUTION™ Cell Culture RNA kit is a critical tool for researchers in academic and biopharma labs. It is available in 96- and 384-well plate formats and can be used with a variety of sample types. About BioEcho Life Sciences GmbH BioEcho Life Sciences is an ISO 9001 certified company specializing in nucleic acid sample preparation tools for life sciences research, agricultural, and industrial applications. Founded in 2016 by a team of industry experts in genomic sample preparation, BioEcho was established with the mission of utilizing its proprietary technologies and technical expertise to overcome the limitations of many standardized methods in molecular biology workflows. BioEcho kits offer customers industry-leading quality, speed, simplicity, and sustainability for the purification of high-quality nucleic acids from a wide variety of samples. Our mission is to provide simple, safe, and sustainable solutions that enable our customers to reveal the unseen and echoing true biology. For more information, visit Sarah Eckenrode BioEcho Life Sciences [email protected] Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
